Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jun 13;6(6):CD013318.
doi: 10.1002/14651858.CD013318.pub2.

Fenofibrate for diabetic retinopathy

Sachiko Y Kataoka  1 , Noemi Lois  2 , Sumihiro Kawano  3 , Yuki Kataoka  4   5   6   7 , Kana Inoue  8 , Norio Watanabe  9
Affiliations

Fenofibrate for diabetic retinopathy

Sachiko Y Kataoka et al. Cochrane Database Syst Rev. .

Abstract

Background: Diabetic retinopathy (DR) remains a major cause of sight loss worldwide, despite new therapies and improvements in the metabolic control of people living with diabetes. Therefore, DR creates a physical and psychological burden for people, and an economic burden for society. Preventing the development and progression of DR, or avoiding the occurrence of its sight-threatening complications is essential, and must be pursued to save sight. Fenofibrate may be a useful strategy to achieve this goal, by reversing diabetes' effects and reducing inflammation in the retina, as well as improving dyslipidaemia and hypertriglyceridaemia. OBJECTIVES: To investigate the benefits and harms of fenofibrate for preventing the development and progression of diabetic retinopathy in people with type 1 (T1D) or type 2 diabetes (T2D), compared with placebo or observation.

Search methods: We searched CENTRAL, MEDLINE, Embase, and three trials registers (February 2022).

Selection criteria: We included randomised controlled trials (RCTs) that included people with T1D or T2D, when these compared fenofibrate with placebo or with observation, and assessed the effect of fenofibrate on the development or progression of DR (or both).

Data collection and analysis: We used standard Cochrane methods for data extraction and analysis. Our primary outcome was progression of DR, a composite outcome of 1) incidence of overt retinopathy for participants who did not have DR at baseline, or 2) advancing two or more steps on the Early Treatment Diabetic Retinopathy Study (ETDRS) severity scale for participants who had any DR at baseline (or both), based on the evaluation of stereoscopic or non-stereoscopic fundus photographs, during the follow-up period. Overt retinopathy was defined as the presence of any DR observed on stereoscopic or non-stereoscopic colour fundus photographs. Secondary outcomes included the incidence of overt retinopathy, reduction in visual acuity of participants with a reduction in visual acuity of 10 ETDRS letters or more, proliferative diabetic retinopathy, and diabetic macular oedema; mean vision-related quality of life, and serious adverse events of fenofibrate. We used GRADE to assess the certainty of evidence.

Main results: We included two studies and their eye sub-studies (15,313 participants) in people with T2D. The studies were conducted in the US, Canada, Australia, Finland, and New Zealand; follow-up period was four to five years. One was funded by the government, the other by industry. Compared to placebo or observation, fenofibrate likely results in little to no difference in progression of DR (risk ratio (RR) 0.86; 95% confidence interval (CI) 0.60 to 1.25; 1 study, 1012 participants; moderate-certainty evidence) in a population with and without overt retinopathy at baseline. Those without overt retinopathy at baseline showed little or no progression (RR 1.00, 95% CI 0.68 to 1.47; 1 study, 804 participants); those with overt retinopathy at baseline found that their DR progressed slowly (RR 0.21, 95% CI 0.06 to 0.71; 1 study, 208 people; test for interaction P = 0.02). Compared to placebo or observation, fenofibrate likely resulted in little to no difference in either the incidence of overt retinopathy (RR 0.91; 95% CI 0.76 to 1.09; 2 studies, 1631 participants; moderate-certainty evidence); or the incidence of diabetic macular oedema (RR 0.39; 95% CI 0.12 to 1.24; 1 study, 1012 participants; moderate-certainty evidence). The use of fenofibrate increased severe adverse effects (RR 1.55; 95% CI 1.05 to 2.27; 2 studies, 15,313 participants; high-certainty evidence). The studies did not report on incidence of a reduction in visual acuity of 10 ETDRS letters or more, incidence of proliferative diabetic retinopathy, or mean vision-related quality of life.

Authors' conclusions: Current, moderate-certainty evidence suggests that in a mixed group of people with and without overt retinopathy, who live with T2D, fenofibrate likely results in little to no difference in progression of diabetic retinopathy. However, in people with overt retinopathy who live with T2D, fenofibrate likely reduces the progression. Serious adverse events were rare, but the risk of their occurrence was increased by the use of fenofibrate. There is no evidence on the effect of fenofibrate in people with T1D. More studies, with larger sample sizes, and participants with T1D are needed. They should measure outcomes that are important to people with diabetes, e.g. change in vision, reduction in visual acuity of 10 ETDRS letters or more, developing proliferative diabetic retinopathy; and evaluating the requirement of other treatments, e.g. injections of anti-vascular endothelial growth factor therapies, steroids.

PubMed Disclaimer

Conflict of interest statement

SYK: none

NL: none

YK: none

SK: none

KI: none

NW: none related to the present review

Figures

1
1
Study selection flow diagram
2
2
Risk of bias graph: review authors' judgements about each risk of bias item, presented as percentages across all included studies
3
3
Risk of bias summary: review authors' judgements about each risk of bias item for each included study
1.1
1.1. Analysis
Comparison 1: Fenofibrate vs placebo (5 year), Outcome 1: Progression of diabetic retinopathy
1.2
1.2. Analysis
Comparison 1: Fenofibrate vs placebo (5 year), Outcome 2: Incidence of overt retinopathy
1.3
1.3. Analysis
Comparison 1: Fenofibrate vs placebo (5 year), Outcome 3: Incidence of DMO
1.4
1.4. Analysis
Comparison 1: Fenofibrate vs placebo (5 year), Outcome 4: Additional treatments for diabetic retinopathy (any laser)
1.5
1.5. Analysis
Comparison 1: Fenofibrate vs placebo (5 year), Outcome 5: Additional treatments for diabetic retinopathy (focal/grid laser)
1.6
1.6. Analysis
Comparison 1: Fenofibrate vs placebo (5 year), Outcome 6: Additional treatments for diabetic retinopathy (panretinal photocoaculation)
1.7
1.7. Analysis
Comparison 1: Fenofibrate vs placebo (5 year), Outcome 7: Additional treatments for diabetic retinopathy (vitrectomy)
1.8
1.8. Analysis
Comparison 1: Fenofibrate vs placebo (5 year), Outcome 8: Discontinuation of the treatment
1.9
1.9. Analysis
Comparison 1: Fenofibrate vs placebo (5 year), Outcome 9: Adverse effects (serious adverse event)
1.10
1.10. Analysis
Comparison 1: Fenofibrate vs placebo (5 year), Outcome 10: Adverse effects (rhabdomyolysis)
1.11
1.11. Analysis
Comparison 1: Fenofibrate vs placebo (5 year), Outcome 11: Adverse effects (hepatic disorder)
1.12
1.12. Analysis
Comparison 1: Fenofibrate vs placebo (5 year), Outcome 12: Adverse effects (pancreatitis)
1.13
1.13. Analysis
Comparison 1: Fenofibrate vs placebo (5 year), Outcome 13: Adverse effects (pulmonary embolism)
1.14
1.14. Analysis
Comparison 1: Fenofibrate vs placebo (5 year), Outcome 14: Adverse effects (myositis)
1.15
1.15. Analysis
Comparison 1: Fenofibrate vs placebo (5 year), Outcome 15: Adverse effects (renal disease needing dialysis)
1.16
1.16. Analysis
Comparison 1: Fenofibrate vs placebo (5 year), Outcome 16: Adverse effects (deep‐vein thrombosis)
See this image and copyright information in PMC

Update of

  • doi: 10.1002/14651858.CD013318

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

References to studies included in this review

ACCORD‐Lipid {published data only}
    1. ACCORD Study Group, ACCORD Eye Study Group, Chew EY, Ambrosius WT, Davis MD, Danis RP, et al. Effects of medical therapies on retinopathy progression in type 2 diabetes. New England Journal of Medicine 2010;363(3):233-44. - PMC - PubMed
    1. ACCORD Study Group, Buse JB, Bigger JT, Byington RP, Cooper LS, Cushman WC, Friedewald WT, et al. Action to control cardiovascular risk in diabetes (ACCORD) trial: design and methods. American Journal of Cardiology 2007;99(12):S21-33. [DOI: 10.1016/j.amjcard.2007.03.003] - DOI - PubMed
    1. ACCORD Study Group, Ginsberg HN, Elam MB, Lovato LC, Crouse JR 3rd, Leiter LA, Linz P, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. New England Journal of Medicine 2010;362(17):1563-74. - PMC - PubMed
    1. Chew EY, Ambrosius WT, Howard LT, Greven CM, Johnson S, Danis RP, et al. Rationale, design, and methods of the action to control cardiovascular risk in diabetes eye study (ACCORD-EYE). American Journal of Cardiology 2007;99(Suppl 12 ):S103-11. - PubMed
    1. Chew EY, Davis MD, Danis RP, Lovato JF, Perdue LH, Greven C, et al. The effects of medical management on the progression of diabetic retinopathy in persons with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) eye study. Ophthalmology 2014;121(12):2443‐51. - PMC - PubMed
FIELD {published data only}
    1. D'Emden M, Li LP, Zannino D, Best J, Keech AC, on behalf of the FIELD Study Investigators. Effect of fenofibrate on cardiovascular events and mortality in women with type 2 diabetes: results from the fenofibrate intervention and event lowering in diabetes (FIELD) study. Diabetes 2009;58(Suppl 1A):A178.
    1. FIELD Study Investigators. The need for a large-scale trial of fibrate therapy in diabetes: the rationale and design of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Cardiovascular Diabetology 2004;3(9):1-11. - PMC - PubMed
    1. ISRCTN64783481. Fenofibrate intervention and event lowering in diabetes. www.isrctn.com/ISRCTN64783481? (first registered 19 October 2004). [DOI: 10.1186/ISRCTN64783481] - DOI
    1. Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005;366(9500):1849-61. - PubMed
    1. Keech AC, Mitchell P, Summanen PA, O'Day J, Davis TM, Moffitt MS, et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet 2007;370(9600):1687‐97. - PubMed

References to studies excluded from this review

ACCORDION 2016 {published data only}
    1. Action to Control Cardiovascular Risk in Diabetes Follow-On (ACCORDION) Eye Study Group and the Action to Control Cardiovascular Risk in Diabetes Follow-On (ACCORDION) Study Group. Persistent effects of intensive glycemic control on retinopathy in type 2 diabetes in the action to control cardiovascular risk in diabetes (ACCORD) follow-on study. Diabetes Care 2016;39(7):1089-100. - PMC - PubMed
ACTRN 12618000592246 {published data only}
    1. ACTRN 12618000592246. A randomised multi-centre placebo controlled trial of fenofibrate for treatment of diabetic macular oedema with economic evaluation (FORTE Study). anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12618000592246 (first received 17 April 2018). [ANZCTR: 12618000592246]
Borona 2021 {published data only}
    1. Bonora BM, Albiero M, Morieri Ml, Cappellari R, Amendolagine FI, Mazzucato M, et al. Fenofibrate increases circulating haematopoietic stem cells in people with diabetic retinopathy: a randomised, placebo-controlled trial. Diabetologia 2021;64:2334-44. - PubMed
Bronson 2010 {published data only}
    1. Bronson DL. Intensifying glucose control and adding fenofibrate to simvastatin each reduced progression of retinopathy in type 2 diabetes. Annals of Internal Medicine 2010;153(10):JC5-10. - PubMed
Cui 2018 {published data only}
    1. Cui Y, Li XD. Efficacy of fenofibrate combined with 23G minimally invasive vitrectomy for diabetic retinopathy. International Eye Science 2018;18(12):2155-9.
Elam 2011 {published data only}
    1. Elam M, Lovato L, Ginsberg H. The ACCORD-Lipid study: implications for treatment of dyslipidemia in type 2 diabetes mellitus. Clinical Lipidology 2011;6(1):9-20. - PMC - PubMed
Fazio 2009 {published data only}
    1. Fazio S. More clinical lessons from the FIELD study. Cardiovascular Drugs and Therapy 2009;23(3):235-41. - PubMed
Feher 2005 {published data only}
    1. Feher MD, Elkeles RS. Fenofibrate in type 2 diabetes: the FIELD study. British Journal of Diabetes and Vascular Disease 2005;5(6):330‐3.
FIELD 2008 {published data only}
    1. Fenofibrate reduces laser treatment needs in patients with diabetic retinopathy. Australian Journal of Pharmacy 2008;89(1061):77.
Fuessl 2008 {published data only}
    1. Fuessl HS. Fenofibrate reduces the need for laser treatment for diabetic retinopathy. MMW-Fortschritte der Medizin 2008;150(13):22.
Grigoryeva 2011 {published data only}
    1. Grigoryeva N, Shklyarov E, Shadrichev F, Kryaneva O. Fenofibrate effect on diabetic retinopathy. European Journal of Ophthalmology. 2011;21(3):344.
Massin 2014 {published data only}
    1. Massin P, Peto T, Ansquer JC, Aubonnet P. Effects of fenofibric acid on diabetic macular edema: the MacuFen study. Ophthalmic Epidemiology 2014;21(5):307‐17. - PubMed
    1. Massin P, Peto T, Le-Malicot K, Ansquer J. Effects of fenofibric acid on diabetic macular edema measured by optical coherence tomography. European Journal of Ophthalmology 2012;22(3):518.
Matthews 2011 {published data only}
    1. Matthews DR. Fenofibrate and statin therapy, compared with placebo and statin, slows the development of retinopathy in type 2 diabetes patients of 10 years duration: the ACCORD study. Evidence-Based Medicine 2011;16(2):45‐6. - PubMed
NCT04140201 {published data only}
    1. NCT04140201. Effect of lipid lowering agents on diabetic retinopathy and cardiovascular risk of diabetic patients. clinicaltrials.gov/ct2/show/study/NCT04140201 (first received 25 October 2019).
NCT04885153 {published data only}
    1. NCT04885153. Effects of oral fenofibrate on retinal thickness and macular volume. clinicaltrials.gov/ct2/show/NCT04885153 (first received 13 May 2021).
O'Connor 2011 {published data only}
    1. O'Connor PJ, Ismail-Beigi F. Near-normalization of glucose and microvascular diabetes complications: data from ACCORD and ADVANCE. Therapeutic Advances in Endocrinology and Metabolism 2011;2(1):17‐26. - PMC - PubMed
Srinivasan 2018 {published data only}
    1. Srinivasan S, Hande P, Shetty J, Murali S. Efficiency of fenofibrate in facilitating the reduction of central macular thickness in diabetic macular edema. Indian Journal of Ophthalmology 2018;66(1):98‐105. - PMC - PubMed
Valentine 2013 {published data only}
    1. Valentine WJ, Pollock RF, Carr E, Aubonnet P, Mitchell P, Keech A. Evaluating the cost-utility of fenofibrate treatment of diabetic retinopathy in Australia. Value in Health 2013;16(7):A442.

References to ongoing studies

FAME 1 EYE {unpublished data only}
    1. ACTRN 12611000249954. The fenofibrate and microvascular event eye (FAME 1 EYE) trial in adults with type 1 diabetes mellitus: a randomised trial in adults with type 1 diabetes mellitus evaluating the effects of daily oral fenofibrate compared with placebo on macular thickness and volume. anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12611000249954 (first received 7 March 2011).
    1. NCT01320345. The fenofibrate and microvascular events in type 1 diabetes eye (FAME 1 EYE) [A randomised trial to evaluate the efficacy on retinopathy and safety of fenofibrate in adults with type 1 diabetes. A multicentre double-blind placebo-controlled study in Australia and internationally.]. clinicaltrials.gov/ct2/show/NCT01320345 (first received 22 March 2011).
NCT03439345 {published and unpublished data}
    1. NCT03439345. Lowering events in non-proliferative retinopathy in Scotland [A randomised placebo-controlled trial of fenofibrate to prevent progression of non-proliferative retinopathy in diabetes]. clinicaltrials.gov/ct2/show/nct03439345 (first received 20 February 2018).
    1. Preiss D, Armitage J, Olson J, Scotland G, Leese G, Colhoun H, et al. LENS-a clinical trial embedded in routine clinical practice to reduce the burden of diabetic eye disease. Trials 2017;18 (Suppl 1):56. [DOI: 10.1186/s13063-017-1902-y] - DOI
NCT04661358 {unpublished data only}
    1. NCT04661358. Fenofibrate for prevention of DR worsening (protocol AF) [A randomized clinical trial evaluating fenofibrate for prevention of diabetic retinopathy worsening]. clinicaltrials.gov/ct2/show/NCT04661358 (first received 10 December 2020).

Additional references

Aiello 2010
    1. Aiello LP, Edwards AR, Beck RW, Bressler NM, Davis MD, Ferris F, et al. Factors associated with improvement and worsening of visual acuity 2 years after focal/grid photocoagulation for diabetic macular edema. Ophthalmology 2010;117(5):946-53. - PMC - PubMed
Blane 1989
    1. Blane G F. Review of European clinical experience with fenofibrate. Cardiology 1989;76(Suppl 1):1-13. - PubMed
Boyer 2014
    1. Boyer DS, Yoon YH, Belfort R Jr, Bandello F, Maturi RK, Augustin AJ. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology 2014;121(10):1904-14. - PubMed
Brown 2021
    1. Brown DM, Wykoff CC, Boyer D, Heier JS, Clark WL, Emanuelli A, et al. Evaluation of intravitreal aflibercept for the treatment of severe nonproliferative diabetic retinopathy: results from the PANORAMA randomized clinical trial. JAMA Ophthalmology 2021;139(9):946-55. - PMC - PubMed
Ciudin 2013
    1. Ciudin A, Hernandez C, Simo R. Molecular implications of the PPARs in the diabetic eye. PPAR Research 2013;2013:686525. [DOI: 10.1155/2013/686525] - DOI - PMC - PubMed
Covidence [Computer program]
    1. Covidence. Version accessed 28 February 2022. Melbourne, Australia: Veritas Health Innovation. Available at www.covidence.org.
Czupryniak 2016
    1. Czupryniak L, Joshi SR, Gogtay JA, Lopez M. Effect of micronized fenofibrate on microvascular complications of type 2 diabetes: a systematic review. Expert Opinion on Pharmacotherapy 2016;17(11):1463-73. - PubMed
Deeks 2022
    1. Deeks JJ, Higgins JP, Altman DG, editor(s) on behalf of the Cochrane Statistical Methods Group. Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s), Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022), Cochrane, 2022. Available at www.training.cochrane.org/handbook.
Duh 2017
    1. Duh EJ, Sun JK, Stitt AW. Diabetic retinopathy: current understanding, mechanisms, and treatment strategies. JCI Insight 2017;2(14):pii: 93751. [DOI: 10.1172/jci.insight.93751] - DOI - PMC - PubMed
Elkjaer 2020
    1. Elkjaer AS, Lynge SK, Grauslund J. Evidence and indications for systemic treatment in diabetic retinopathy: a systematic review. Acta Ophthalmologica 2020;98(4):329-36. - PubMed
ETDRS 1991
    1. Early Treatment Diabetic Retinopathy Study Research Group. Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12. Ophthalmology 1991;98(Suppl 5 ):823-33. - PubMed
Evans 2014
    1. Evans JR, Michelessi M, Virgili G. Laser photocoagulation for proliferative diabetic retinopathy. Cochrane Database of Systematic Reviews 2014, Issue 11. Art. No: CD011234. [DOI: 10.1002/14651858.CD011234.pub2] - DOI - PMC - PubMed
Glanville 2006
    1. Glanville JM, Lefebvre C, Miles JN, Camosso-Stefinovic J. How to identify randomized controlled trials in MEDLINE: ten years on. Journal of the Medical Library Association 2006;94(2):130-6. - PMC - PubMed
Gong 2016
    1. Gong Y, Shao Z, Fu Z, Edin ML, Sun Y, Liegl RG, et al. Fenofibrate inhibits cytochrome P450 epoxygenase 2C activity to suppress pathological ocular angiogenesis. EBioMedicine 2016;13:201-11. - PMC - PubMed
GRADEpro GDT  [Computer program]
    1. GRADEpro GDT. Version accessed 30 June 2022. Hamilton (ON): McMaster University (developed by Evidence Prime). Available at gradepro.org.
Gross 2015
    1. Gross JG, Glassman AR, Jampol LM, Inusah S, Aiello LP, Antoszyk AN, et al. Panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: a randomized clinical trial. JAMA 2015;314(20):2137-46. - PMC - PubMed
Guay 1999
    1. Guay RP. Micronized fenofibrate: a new fibric acid hypolipidemic agent. Annals of Pharmacotherapy 1999;33(10):1083-103. - PubMed
Guyatt 2011
    1. Guyatt GH, Oxman AD, Kunz R, Brozek J, Alonso-Coello P, Rind D, et al. GRADE guidelines 6. Rating the quality of evidence—imprecision. Journal of Clinical Epidemiology 2011;64(12):1283-93. - PubMed
Heintz 2010
    1. Heintz E, Wirehn AB, Peebo BB, Rosenqvist U, Levin LA. Prevalence and healthcare costs of diabetic retinopathy: a population-based register study in Sweden. Diabetologia 2010;53(10):2147-54. - PubMed
Higgins 2017
    1. Higgins JP, Altman DG, Sterne JA, editor(s). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS, editor(s), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane, 2017. Available from training.cochrane.org/handbook/archive/v5.2.
Hu 2013
    1. Hu Y, Chen Y, Ding L, He X, Takahashi Y, Gao Y, et al. Pathogenic role of diabetes-induced PPAR-alpha down-regulation in microvascular dysfunction. Proceedings of the National Academy of Sciences of the United States of America 2013;110(38):15401-6. - PMC - PubMed
Liu 2017
    1. Liu Q, Zhang F, Zhang X, Cheng R, Ma JX, Yi J, et al. Fenofibrate ameliorates diabetic retinopathy by modulating Nrf2 signaling and NLRP3 inflammasome activation. Molecular and Cellular Biochemistry 2018;445(1-2):105-15. - PubMed
Maturi 2021
    1. Maturi RK, Glassman AR, Josic K, Antoszyk AN, Blodi BA, Jampol LM, et al. Effect of intravitreous anti-vascular endothelial growth factor vs sham treatment for prevention of vision-threatening complications of diabetic retinopathy: the protocol W randomized clinical trial. JAMA Ophthalmology 2021;139(7):E1-12. - PMC - PubMed
McCulloch 2017
    1. McCulloch DK, Nathan DM, Trobe J, Mulder JE. Diabetic retinopathy: pathogenesis. www.uptodate.com/contents/diabetic-retinopathy-pathogenesis (accessed 14 January 2019).
Review Manager 2020 [Computer program]
    1. Review Manager (RevMan). Version 5.4. The Cochrane Collaboration, 2020.
RevMan Web 2023 [Computer program]
    1. Review Manager Web (Rev Man Web). Version 5.3.1. The Cochrane Collaboration, 2023. Available at revman.cochrane.org.
Romero‐Aroca 2016
    1. Romero-Aroca P, la Riva-Fernandez S, Valls-Mateu A, Sagarra-Alamo R, Moreno-Ribas A, Soler N, et al. Cost of diabetic retinopathy and macular oedema in a population, an eight year follow up. BMC Ophthalmology 2016;16:136. - PMC - PubMed
Schmier 2009
    1. Schmier JK, Covert DW, Lau EC, Matthews GP. Medicare expenditures associated with diabetes and diabetic retinopathy. Retina 2009;29(2):199-206. - PubMed
Schünemann 2022
    1. Schünemann HJ, Higgins JPT, Vist GE, Glasziou P, Akl EA, Skoetz N, et al. Chapter 14: Completing ‘Summary of findings’ tables and grading the certainty of the evidence. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022. Available from training.cochrane.org/handbook.
Sivaprasad 2017
    1. Sivaprasad S, Prevost AT, Vasconcelos JC, Riddell A, Murphy C, Kelly J, et al. Clinical efficacy of intravitreal aflibercept versus panretinal photocoagulation for best corrected visual acuity in patients with proliferative diabetic retinopathy at 52 weeks (CLARITY): a multicentre, single-blinded, randomised, controlled, phase 2b, non-inferiority trial. Lancet 2017;389(10085):2193-203. - PubMed
Stitt 2016
    1. Stitt AW, Curtis TM, Chen M, Medina RJ, McKay GJ, Jenkins A, et al. The progress in understanding and treatment of diabetic retinopathy. Progress in Retinal and Eye Research 2016;51:156-86. - PubMed
Su 2019
    1. Su XJ, Han L, Qi YX, Liu HW. Efficacy of fenofibrate for diabetic retinopathy: a systematic review protocol. Medicine 2019;98(14):e14999. - PMC - PubMed
Tan 2017
    1. Tan GS, Cheung N, Simó R, Cheung GC, Wong TY. Diabetic macular oedema. Lancet Diabetes and Endocrinology 2017;5(2):143-55. - PubMed
Teo 2021
    1. Teo ZL, Tham YC, Yu M, Chee ML, Rim TH, Cheung N, et al. Global prevalence of diabetic retinopathy and projection of burden through 2045: systematic review and meta-analysis. Ophthalmology 2021;128(11):1580-91. - PubMed
Virgili 2018
    1. Virgili G, Parravano M, Evans JR, Gordon I, Lucenteforte E. Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis. Cochrane Database of Systematic Reviews 2018, Issue 10. Art. No: CD007419. [DOI: 10.1002/14651858.CD007419.pub6] - DOI - PMC - PubMed
Woung 2010
    1. Woung LC, Tsai CY, Chou HK, Tsai MT, Tsai WH, Chou P, et al. Healthcare costs associated with progressive diabetic retinopathy among National Health Insurance enrollees in Taiwan, 2000-2004. BMC Health Service Research 2010;10:136. - PMC - PubMed
Zhang 2017
    1. Zhang X, Low S, Kumari N, Wang J, Ang K, Yeo D, et al. Direct medical cost associated with diabetic retinopathy severity in type 2 diabetes in Singapore. PLoS One 2017;12(7):e0180949. - PMC - PubMed

References to other published versions of this review

Inoue 2019
    1. Inoue K, Kataoka SY, Kawano S, Furukawa TA, Lois N, Watanabe N. Fenofibrate for diabetic retinopathy. Cochrane Database of Systematic Reviews 2019, Issue 4. Art. No: CD013318. [DOI: 10.1002/14651858.CD013318] - DOI - PMC - PubMed

Publication types

MeSH terms